TLX
Telix Pharmaceuticals Limited
NASDAQ: TLX · HEALTHCARE · BIOTECHNOLOGY
$10.43
-0.10% today
Updated 2026-04-29
Market cap
$3.53B
P/E ratio
—
P/S ratio
4.40x
EPS (TTM)
$-0.02
Dividend yield
—
52W range
$6 – $19
Volume
0.3M
Telix Pharmaceuticals Limited (TLX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 6
Last 6 quarters
Avg EPS surprise
-36.0%
Last 4 quarters
Revenue YoY growth
+4.4%
Most recent quarter
EPS YoY growth
-33.3%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+9.0%
Last 3 reports
Positive reaction rate
100%
3 of 3 quarters
Largest single-day move
+15.4%
2025-10-14
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-18 | $0.04 | -48.1% | $6.42 | $6.71 | +4.5% |
| 2025-10-14 | $-0.09 | +35.3% | $9.54 | $11.01 | +15.4% |
| 2025-08-20 | $0.01 | -95.3% | $11.30 | $12.09 | +7.0% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $0.08 | $0.04 | -48.1% | $620.44M | +4.4% |
| 2025-09-30 | $-0.14 | $-0.09 | +35.3% | — | — |
| 2025-06-30 | $0.21 | $0.01 | -95.3% | $593.11M | — |
| 2025-03-31 | $0.00 | $0.09 | — | — | — |
| 2024-12-31 | $0.00 | $0.06 | — | $594.24M | — |
| 2024-09-30 | $0.00 | $0.00 | — | — | — |
Frequently asked questions
Has Telix Pharmaceuticals Limited beaten earnings estimates?
Telix Pharmaceuticals Limited has beaten Wall Street EPS estimates in 4 of its last 6 quarterly reports, with an average EPS surprise of -36.0% over the last 3 quarters.
How does TLX stock react to earnings?
TLX stock has moved an average of +9.0% in the trading day following earnings over its last 3 reports, with positive reactions in 100% of those quarters.
What is Telix Pharmaceuticals Limited's revenue growth rate?
Telix Pharmaceuticals Limited reported year-over-year revenue growth of +4.4% in its most recent quarter, with EPS growing -33.3% year-over-year.